Determination of carcinogen-DNA adducts by immunoassay.
Poirier
M C
MC
National Cancer Institute, Bethesda, MD.
Liou
S H
SH
Reed
E
E
Strickland
P T
PT
Tockman
M S
MS
D000911:Antibodies, Monoclonal; D000941:Antigens / Q000032:analysis / Q000276:immunology; D001564:Benzo(a)pyrene / Q000032:analysis / Q000097:blood / Q000276:immunology; D001773:Blood Cells / Q000032:analysis / Q000276:immunology; D002273:Carcinogens / Q000032:analysis*; D002467:Cell Nucleus / Q000032:analysis / Q000276:immunology; D002945:Cisplatin / Q000032:analysis / Q000097:blood / Q000627:therapeutic use; D004247:DNA / Q000032:analysis* / Q000097:blood / Q000187:drug effects / Q000276:immunology; D018736:DNA Adducts; D004249:DNA Damage; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D008297:Male; D009369:Neoplasms / Q000032:analysis / Q000097:blood / Q000188:drug therapy; D012074:Remission Induction; D015208:Smoke Inhalation Injury / Q000097:blood / Q000276:immunology
D000911:Antibodies, Monoclonal; D000941:Antigens; D002273:Carcinogens; D018736:DNA Adducts; D007106:Immune Sera; C056612:benzo(a)pyrene-DNA adduct; D001564:Benzo(a)pyrene; D004247:DNA; D002945:Cisplatin